Kate O'Connell (Dublin Bay South, Fine Gael) | Oireachtas source

When Deputy Durkan was asking about the price of the orphan or high-tech drugs, Mr. Mulvany spoke of the robust assessment that happens, I assume through the National Centre for Pharmacoeconomics. That is all good. Am I correct in saying that there is scope for a Minister to override the economic decision of that group? If the quality-adjusted life year, QALY, number comes back as not being value for money, the Minister can override the decision of the National Centre for Pharmacoeconomics, NCPE.